skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration
  • Close Icon

Refine Results

Clear All

Specialism

Show More

Resources

Show More

Show More

Products

Show More

Show More

14 Total results for product and free and sample content found

Scrip: 世界の医療用医薬品&製薬産業に関するニュース

Another Alzheimer's Setback As Roche And Lilly Drugs Fail

As Biogen moves to file its controversial amyloid drug aducanumab for approval in the US, two similar investigational Alzheimer's drugs – Eli Lilly's solanezumab and Roche's gantenerumab – did not slow memory loss or cognitive decline in a rare, inherited form of the disease.

Topic Alzheimer's Disease

Scrip: 世界の医療用医薬品&製薬産業に関するニュース

Biogen, Eisai Report BAN2401 Seemingly Positive In Alzheimer's; Others Skeptical

Biogen, Eisai Report BAN2401 Seemingly Positive In Alzheimer's; Others Skeptical

Further new data for the Biogen and Eisai drug BAN2401 appear to show it significantly reduces amyloid plaque and cognitive declines in Alzheimer's patients in a dose-dependent manner, but a lot of questions – and skepticism about the data – remain.

Topic alzheimers clinical-trials research

Scrip: 世界の医療用医薬品&製薬産業に関するニュース

AbbVie Calico Extend Their Collaboration On Aging

AbbVie Calico Extend Their Collaboration On Aging

The pharma and the Google spinout focused on aging are adding $1bn in funding to their 2014 collaboration, which has yielded more than two dozen preclinical candidates so far.

Topic alzheimers

Pink Sheet: 世界の薬事規制と承認審査に関するニュース

Alzheimer's Biomarkers Gain Prominence In Drug Development Guidance

Alzheimer's Biomarkers Gain Prominence In Drug Development Guidance

US FDA revises draft guidance issued in 2013 to allow research targeting cognition as single endpoint and studies solely evaluating biomarkers; document offers 'potential for multiple advances,' Alzheimer's Association says.

Topic alzheimers

In Vivo: 医療用医薬品・医療機器産業の経営層向けニュース

Curing What Hinders Alzheimer’s Drug Development

Curing What Hinders Alzheimer’s Drug Development

Biomarkers will be key to winning the race to a successful AD drug. Even then, drugmakers must build the infrastructure for getting therapy to the right patients at the right time.

Topic alzheimers drug-development-landscape

Sitetrove: 治験責任医師と治験施設情報のデータベース

Sitetrove Infographic Roundup - Issue 4 - November - 2017

Sitetrove Infographic Roundup - Issue 4 - November - 2017

November is National Alzheimer’s Disease (AD) Awareness Month. Sitetrove wants to raise awareness by going purple! This infographic offers an overview of the current global investigator landscape and how AD trial experience has shifted over the last 10 years

Topic Alzheimers

Biomedtracker: 開発中医薬品をFDA承認確率で評価

BMT Q4 Outlook Report

BMT Q4 Outlook Report

In this report, we cover catalysts from 21 drugs expected to occur in Q4 2017. For each drug, the likelihood of Phase/PDUFA review success and overall Likelihood of Approval (LOA) given their particular phase, drug class, and disease group are provided.

Topic Alzheimers Cancer Drug approval

Biomedtracker: 開発中医薬品をFDA承認確率で評価

Report Extract: Q3 2017 Outlook Report

Report Extract: Q3 2017 Outlook Report

In this report, we cover catalysts from 21 drugs expected to occur in Q3 2017. For each drug, the likelihood of Phase/PDUFA review success and overall Likelihood of Approval (LOA) given their particular phase, drug class, and disease group are provided.

Topic alzheimers cancer drug-approval

お問い合わせ&レポートストア

専任スタッフによるデモンストレーションを兼ねたサービスの詳しいご説明、または無料トライアルを常時受け付けています。ご希望の場合は下記のフォームよりお気軽にお申し込みください。

*一部のサービスでは無料トライアルをご利用になれません。

ご質問等ございましたらお気軽にご連絡下さい。

日本(平日:9時~18時)
電話:+81 (0)3 6273 4260
Email:inquiry.jp@informa.com

オンラインショップのレポートストアでは、医療用医薬品の市場調査・分析レポートを常時1000本以上販売しています。レポート1本単位で購入でき、オンラインでご提供いたします。

お探しの情報が見つからない場合はお問い合わせ先までお気軽にご連絡ください。